Vor Biopharma's (VOR) Sell (D-) Rating Reaffirmed at Weiss Ratings

Key Points

• Vor Biopharma has had its "sell (D-)" rating reaffirmed by Weiss Ratings, while other analysts have varied in their assessments, with Zacks upgrading to "hold" and Wall Street Zen downgrading to "strong sell."
• The stock has experienced a 1.2% decline trading at $33.40 recently, with a consensus target price of $113.83 based on multiple analysts' ratings.
• Vor Biopharma reported a significant loss of ($43.60) earnings per share (EPS), missing the consensus estimate by over $32, indicating financial challenges ahead.

Vor Biopharma (NASDAQ:VOR - Get Free Report)'s stock had its "sell (d-)" rating reissued by investment analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Other research analysts have also recently issued reports about the stock. Zacks Research upgraded shares of Vor Biopharma from a "strong sell" rating to a "hold" rating in a report on Wednesday, September 10th. Wall Street Zen downgraded shares of Vor Biopharma to a "strong sell" rating in a research note on Saturday, June 28th. Wedbush reaffirmed an "outperform" rating on shares of Vor Biopharma in a research note on Thursday, June 26th. Stifel Nicolaus raised Vor Biopharma from a "hold" rating to a "buy" rating and set a $55.00 price objective on the stock in a research note on Wednesday, September 24th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $60.00 target price on shares of Vor Biopharma in a research report on Thursday, August 14th. Five investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Vor Biopharma has a consensus rating of "Hold" and a consensus target price of $113.83.

Vor Biopharma Trading Down 1.2%

VOR traded down $0.40 during trading on Wednesday, reaching $33.40. The company had a trading volume of 436,485 shares, compared to its average volume of 391,343. The company has a market capitalization of $228.79 million, a PE ratio of -0.12 and a beta of 2.07. The business's 50 day moving average is $38.14. Vor Biopharma has a 52 week low of $2.62 and a 52 week high of $65.80.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($43.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($11.40) by ($32.20).

Insider Buying and Selling

In other Vor Biopharma news, major shareholder Reprogrammed Interchange Llc sold 27,624 shares of the business's stock in a transaction that occurred on Tuesday, October 7th. The shares were sold at an average price of $33.84, for a total transaction of $934,796.16. Following the sale, the insider owned 1,498,921 shares of the company's stock, valued at approximately $50,723,486.64. The trade was a 1.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last ninety days, insiders have sold 897,057 shares of company stock valued at $17,773,312. 0.45% of the stock is owned by company insiders.

Hedge Funds Weigh In On Vor Biopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new stake in Vor Biopharma during the 2nd quarter valued at about $66,000. Money Concepts Capital Corp increased its holdings in Vor Biopharma by 106.1% in the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after buying an additional 26,535 shares during the period. Goldman Sachs Group Inc. raised its position in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after buying an additional 58,247 shares during the last quarter. OMERS ADMINISTRATION Corp purchased a new position in Vor Biopharma during the 1st quarter worth approximately $100,000. Finally, Two Sigma Investments LP lifted its stake in Vor Biopharma by 18.9% during the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock valued at $181,000 after acquiring an additional 25,930 shares during the period. Hedge funds and other institutional investors own 97.29% of the company's stock.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.